PATH & MMV set date for eliminating relapsing malaria

PATH & MMV set date for eliminating relapsing malaria
Credit: Shutterstock.com/ Tacio Philip Sansonovsk

Medicines for Malaria Venture (MMV) and healthcare non-profit PATH have launched a five-year initiative to support countries in elimination of Plasmodium vivax (P. vivax) malaria.

The VivAccess initiative is part of the larger global effort to support malaria-endemic countries in the adoption and use of new and existing tools, to facilitate well-tolerated and effective radical cure to prevent relapse.

The work is funded by the Bill & Melinda Gates Foundation.

  1. vivax is the most frequently occurring species of malaria parasite outside of sub-Saharan Africa, putting approximately 2.5 billion people at risk and causing around 7.5 million infections a year.

The goal of VivAccess is to support introduction and increased access to the suite of radical cure products to address these challenges.

“Because one infection caused by the P. vivax parasite has the uncanny ability to cause a patient to relapse in the absence of a new infective mosquito bite, it amplifies the burden of malaria, placing a huge burden on the individuals, communities and countries it infects,” said George Jagoe, Executive Vice President, Access & Product Management at MMV.

“New tools to stop this cycle of disease have been developed, and more are in development. VivAccess is set to accelerate their access to those in need and in doing so protect patients from relapses and support countries to move towards malaria elimination.”

Through VivAccess, the partnership will continue to work closely with the World Health Organisation, National Malaria Control Programs, and country-based healthcare partners to support the introduction and use of these effective tools, which include malaria diagnostics, G6PD diagnostics, blood-stage drugs, and liver-stage radical-cure drugs.

Guided by the leadership of national health agencies, VivAccess will provide support in terms of market analytics, technical expertise, and product delivery coordination as countries seek to introduce effective radical cure into national malaria protocols and accelerate progress towards their malaria elimination goals.

In the process, the initiative will strengthen national and local capacities in alignment with the WHO malaria strategic agenda.